Nu Skin Enterprises, Inc. (NUS) SEC Filings & Earnings Calls
EquiReason read 15 Nu Skin Enterprises, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-21 — Reported a director or officer change (departure, election, appointment or pay arrangement).
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 233.2M
- P/E TTM
- —
- Dividend yield
- 5.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
21 Aug 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Temporary leadership gap in global sales function may affect sales execution and customer relationships.
“Executive VP and President of Global Sales on medical leave; interim leadership by COO/CLO.”
10 Aug 202610-QNu Skin reported a 17.1% YoY revenue decline, a net loss of $249.8M driven by $78.9M goodwill impairment and $167.5M valuation allowance, and a 14% drop in Customers.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $320M | -17% y/y |
| Net income (loss) · Q2-2026 | $-250M | -1284% y/y |
| Operating cash flow · H1-2026 | $7M | -81% y/y |
| Customers · Q2-2026 | 660,037 | -14% y/y |
| Paid Affiliates · Q2-2026 | 120,291 | -8% y/y |
| Sales Leaders · Q2-2026 | 26,998 | -9% y/y |
| Gross profit margin · Q2-2026 | 68.2% | |
| Selling expenses as % of revenue · Q2-2026 | 33.7% | |
| Segment contribution margin · Q2-2026 | 18.7% | |
| Americas segment revenue · Americas · Q2-2026 | $60M | -18% y/y |
Risks flagged
Goodwill impairment risk
“we recorded a non-cash goodwill impairment charge of $78.9 million in the second quarter of 2026.” · word for word
Deferred tax asset valuation allowance
“we established a $167.5 million valuation allowance against its U.S. deferred tax assets as it was determined to be more likely than not that these assets will not be realized.” · word for word
Leverage covenant tightening
“The Credit Agreement requires the Company to maintain a consolidated leverage ratio not exceeding 2.25 to 1.00” · word for word
China repatriation risk
“in Mainland China, we are unable to repatriate cash from current operations in the form of dividends until we file the necessary statutory financial statements for the relevant period.” · word for word
10 Aug 20268-K · 2.02Q2 2026 revenue $320.1M (-17.1% YoY), EPS $(5.14) or $0.20 adjusted vs $0.43; customers -14%, paid affiliates -8%, sales leaders -9%; guidance cut for FY26 revenue to $1.28-1.35B and adjusted EPS $0.70-0.90.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $320M | -17% y/y |
| Gross Margin · Q2-2026 | 68.2% | |
| Operating Margin · Q2-2026 | -18.5% | |
| Earnings Per Share (EPS) · Q2-2026 | $-5.14 | -1295% y/y |
| Customers · Q2-2026 | 660,037 | -14% y/y |
| Paid Affiliates · Q2-2026 | 120,291 | -8% y/y |
| Sales Leaders · Q2-2026 | 26,998 | -9% y/y |
| Selling Expenses · Q2-2026 | 33.7% | |
| G&A Expenses · Q2-2026 | 28.4% | |
| Interest Expense · Q2-2026 | $3M | +32% y/y |
Guidance
FY26 revenue $1.28-1.35B (prior not stated but implies cut from earlier guidance); FY26 adjusted EPS $0.70-0.90; Q3 revenue $310-340M; Q3 adjusted EPS $0.10-0.20
Guidance cut for FY26 revenue and adjusted EPS; Q3 outlook also weak.
Risks flagged
Sustained revenue decline and customer attrition risk further deterioration.
“Revenue -17.1% YoY; Customers -14%”
Non-cash impairment charge indicates potential asset overvaluation.
“EPS $(5.14) includes non-cash impairment charge”
Negative operating margin even excluding impairment suggests underlying profitability issues.
“Operating Margin 6.1% ex-impairment vs 8.0% prior year”
29 May 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersopen
Risks flagged
Potential shareholder dilution from increased equity plan shares.
“Share authorization increased by 2,850,000 shares.”
8 May 202610-QRevenue $321M (-12% y/y); Net Income $2M (-98% y/y); Gross Margin 66.9open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $321M | -12% y/y |
| Net Income · Q1-2026 | $2M | -98% y/y |
| Gross Margin · Q1-2026 | 66.9% | |
| Customers · Q1-2026 | 669,535 | -14% y/y |
| Paid Affiliates · Q1-2026 | 120,850 | -8% y/y |
| Sales Leaders · Q1-2026 | 26,915 | -13% y/y |
| Operating Cash Flow · Q1-2026 | $-4M | |
| Capital Expenditures · Q1-2026 | $14M | |
| Segment Revenue - Americas · Americas · Q1-2026 | $58M | -16% y/y |
| Segment Revenue - Mainland China · Mainland China · Q1-2026 | $45M | -6% y/y |
Risks flagged
Macroeconomic demand weakness across key markets
“The declines for the three-month period ended March 31, 2026 were largely driven by the continued macroeconomic challenges we have been facing in our markets, which have negatively impacted consumer spending and customer acquisition.” · word for word
Tariff uncertainty disrupting manufacturing orders
“customer order delays related to the tariff and associated economic uncertainty.” · word for word
Transformation execution risk
“we have experienced headwinds from the transformation process.” · word for word
China market shift to online marketplaces
“a continued shift of market consumer awareness and demand to online product marketplaces.” · word for word
South Korea political instability and regulatory compliance
“Our South Korea market was challenged by difficult macroeconomic trends, including inflationary pressures, political instability, and our associated price increases which negatively impacted our revenue” · word for word
7 May 20268-K · 2.02Nu Skin Q1 2026: revenue $320.6M (-12% YoY), EPS $0.04 ($0.14 ex-items). Customers -14%, Paid Affiliates -8%, Sales Leaders -13%. Gross margin 66.9% (67.9% ex-items) vs 67.8% prior. Q2 guidance $330-360M, FY26 $1.35-1.50B. Maintained annualearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $321M | -12% y/y |
| Earnings Per Share (EPS) · Q1-2026 | $0.04 | -98% y/y |
| Customers · Q1-2026 | 669,535 | -14% y/y |
| Paid Affiliates · Q1-2026 | 120,850 | -8% y/y |
| Sales Leaders · Q1-2026 | 26,915 | -13% y/y |
| Gross Margin · Q1-2026 | 66.9% | |
| Operating Margin · Q1-2026 | 1.3% |
Guidance
Q2 2026 Revenue $330-360M; Q2 2026 EPS $0.15-0.25; FY2026 Revenue $1.35-1.50B; FY2026 EPS $0.70-1.10 ($0.80-1.20 ex-items)
Maintaining annual guidance on adjusted basis; Q2 guidance implies continued revenue decline; management expresses confidence in strategic initiatives but acknowledges volatility
Risks flagged
Continued decline in customer base and sales force; revenue down 12% YoY
“Customers 669,535; (14)%; Paid Affiliates 120,850; (8)%; Sales Leaders 26,915; (13)%” · word for word
Volatile operating environment; reliance on new product launch (Prysm iO) for turnaround
“operating in a volatile environment; we are focused on empowering our sales leaders to scale our intelligent wellness platform with our latest innovation, Prysm iO”
27 Mar 20268-K · 1.01, 2.03Nu Skin Enterprises entered into a Second Amendment and Restatement Agreement for its credit agreement with Bank of America, refinancing existing debt obligations.open
Risks flagged
Amendment to credit agreement may indicate financial stress or need for covenant relief.
“Second Amendment and Restatement Agreement dated March 27, 2026.”
Increased leverage or financial obligation could pressure cash flows.
“Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.” · word for word
20 Mar 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
CFO departure risk: loss of key financial leadership during transformation and product launch period
“CFO resigned effective immediately; interim CFO appointed with limited public company CFO experience”
9 Mar 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Key person risk: expanded role combines COO and legal functions, creating concentration
“Clark now holds both COO and Chief Legal Officer roles”
13 Feb 202610-KSales Leaders (global) 30,045; Key Sales Leaders (global highest level) 198; Key Sales Leaders (Mainland China) 60open
Figures in the filing · each found in the filing text
| Sales Leaders (global) · Global · Q4-2025 | 30,045 | |
| Key Sales Leaders (global highest level) · Global · FY2025 | 198 | |
| Key Sales Leaders (Mainland China) · Mainland China · FY2025 | 60 |
Risks flagged
FTC regulatory action risk
“The FTC issued a Notice of Proposed Rulemaking and an Advanced Notice of Proposed Rulemaking regarding potential rules governing earnings claims for multi-level marketers.” · word for word
Social media platform dependency risk
“Due to concerns with multi-level marketing, the TikTok and WhatsApp Business platforms’ community guidelines prohibit content related to multi-level marketing.” · word for word
China regulatory and economic risk
“The regulatory environment in Mainland China continues to be challenging and restrictive.” · word for word
Sales force classification risk
“In 2024, a regulation of the U.S. Department of Labor went into effect that alters the employee vs. independent contractor analysis under the Fair Labor Standards Act” · word for word
12 Feb 20268-K · 2.02Revenue $370M (-17% y/y); Earnings Per Share (EPS) $0.29; Customers 748,796 (-10% y/y); Guidance: Q1 2026 revenue $320-340M (-12% to -7% YoY); 2026 revenue $1.35-1.50B (-9% to +1%); Q1 EPS $0.10-0.20; 2026 EPS $0.80-1.20earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $370M | -17% y/y |
| Earnings Per Share (EPS) · Q4-2025 | $0.29 | |
| Customers · Q4-2025 | 748,796 | -10% y/y |
| Paid Affiliates · Q4-2025 | 129,311 | -11% y/y |
| Sales Leaders · Q4-2025 | 30,045 | -19% y/y |
| Gross Margin · Q4-2025 | 70.7% | |
| Operating Margin · Q4-2025 | 6.3% | |
| Full Year Revenue · FY2025 | $1.49B | -14% y/y |
| Full Year EPS · FY2025 | $3.18 |
Guidance
Q1 2026 revenue $320-340M (-12% to -7% YoY); 2026 revenue $1.35-1.50B (-9% to +1%); Q1 EPS $0.10-0.20; 2026 EPS $0.80-1.20
Near-term Q1 guidance shows continued decline; full-year guidance implies H2 recovery driven by Prysm iO launch and India expansion
Risks flagged
Continued customer and affiliate attrition: customers -10%, paid affiliates -11%, sales leaders -19% YoY
“Customers 748,796 (-10%); Paid Affiliates 129,311 (-11%); Sales Leaders 30,045 (-19%)”
Revenue decline persists: Q4 -16.9% YoY, full year -14.3%
“Q4 revenue $370.3M vs $445.6M; full year $1.49B vs $1.74B”
Guidance implies continued Q1 decline: Q1 2026 revenue midpoint $330M vs Q1 2025 likely ~$400M
“Q1 2026 guidance $320-340M vs prior year Q1 revenue (estimated ~$400M based on full-year trajectory)”
7 Nov 202510-QNu Skin reported Q3 2025 revenue of $364.2M, down 15% YoY, with broad-based declines in customers, affiliates, and sales leaders due to macroeconomic headwinds and transformation disruption.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $364M | -15% y/y |
| Net Income · Q3-2025 | $17M | +106% y/y |
| Operating Cash Flow · 9M-2025 | $64M | -26% y/y |
| Customers · Q3-2025 | 746,256 | -10% y/y |
| Paid Affiliates · Q3-2025 | 130,096 | -13% y/y |
| Sales Leaders · Q3-2025 | 31,150 | -19% y/y |
| Nu Skin Gross Margin · Nu Skin · Q3-2025 | 77.7% | |
| Consolidated Gross Margin · Q3-2025 | 70.5% | |
| Capital Expenditures · 9M-2025 | $24M | |
| Cash and Cash Equivalents · Q3-2025 | $253M |
Risks flagged
China revenue concentration and channel shift
“Our Mainland China market continued to be challenged during the first nine months of 2025, with ongoing macroeconomic factors, the associated decrease in consumer spending and a continued shift of market consumer awareness and demand to online product marketplaces.” · word for word
Transformation disruption
“we have experienced headwinds from the transformation process.” · word for word
Tariff cost pressure
“While we remain focused on mitigating the impacts of the tariffs, we currently estimate approximately $2 million of incremental cost pressure for the full year 2025.” · word for word
South Korea political instability and inflation
“Our South Korea market was challenged by difficult macroeconomic trends, including inflationary pressures, political instability, and our associated price increases which negatively impacted our revenue” · word for word
6 Nov 20258-K · 2.02Revenue $364M (-15% y/y); Earnings Per Share (EPS) $0.34; Customers 746,256 (-10% y/y); Guidance: FY2025 revenue $1.48-1.51B (narrowed); EPS $3.15-3.25 ($1.25-1.35 adjusted); Q4 revenue $365-400M, EPS $0.25-0.35earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $364M | -15% y/y |
| Earnings Per Share (EPS) · Q3-2025 | $0.34 | |
| Customers · Q3-2025 | 746,256 | -10% y/y |
| Paid Affiliates · Q3-2025 | 130,096 | -13% y/y |
| Sales Leaders · Q3-2025 | 31,150 | -19% y/y |
| Gross Margin · Q3-2025 | 70.5% | |
| Operating Margin · Q3-2025 | 5.9% |
Guidance
FY2025 revenue $1.48-1.51B (narrowed); EPS $3.15-3.25 ($1.25-1.35 adjusted); Q4 revenue $365-400M, EPS $0.25-0.35
Guidance narrowed based on year-to-date performance; Q4 and full-year ranges tightened
Risks flagged
Continued customer and affiliate attrition: customers -10%, paid affiliates -13%, sales leaders -19% YoY
“Customers 746,256 (-10%); Paid Affiliates 130,096 (-13%); Sales Leaders 31,150 (-19%)”
Revenue decline persists: Q3 -15.3% YoY
“Q3 revenue $364.2M vs $430.1M”
Guidance implies continued Q4 decline: Q4 midpoint $382.5M vs prior year Q4 $445.6M (-14%)
“Q4 guidance $365-400M vs prior year Q4 $445.6M”
Nu Skin Enterprises, Inc. — questions
- What did Nu Skin Enterprises, Inc. file recently?
- 15 SEC filings in the last 12 months. Latest: 8-K on 2026-08-21 — Reported a director or officer change (departure, election, appointment or pay arrangement)
Every figure on this page comes from Nu Skin Enterprises, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.